Regenerex Pharma, Inc. (OTC: RGPX), a leading innovator in advanced wound closure systems for chronic wounds, today announced that it has entered into a binding supply and development agreement with Holista Colltech Ltd. of Perth, Australia.

Under terms of the agreement, Holista will exclusively manufacture and supply its proprietary ovine collagen, including its patented 300 kDa intact collagen and nano-collagen technologies, for Regenerex’s use in the development, clinical testing, and global distribution of advanced wound care products. The initial commercial focus will be the United States, with expansion into other global markets to follow.

Key Terms of the Agreement

- Exclusivity: Regenerex has exclusive worldwide rights to market Holista’s collagen products for wound care applications.

- Minimum Purchase Commitments: Regenerex is required to purchase a minimum of USD50,000 in 2025, scaling to USD3 million in 2026, USD6 million in 2027, and USD9 million annually from 2028 onwards.

- Clinical Development: Regenerex will conduct and fund clinical studies and regulatory approvals with the U.S. FDA and other relevant authorities.

- Joint Innovation: Both companies will collaborate on new applications of nano-collagen in advanced wound care, with joint ownership of any resulting intellectual property.

- Manufacturing: Holista’s ovine collagen will be drawn down from stocks from its manufacturing facility in Collie (WA) and nano-collagen to be produced in Malaysia, under international GMP and halal certification standards.

- Termination: The agreement runs for the life of the relevant patents and may be terminated earlier, including for convenience on 90 days’ notice or for breach, insolvency or by mutual agreement.